:: Volume 21, Issue 4 (Iranian South Medical Journal 2018) ::
Iran South Med J 2018, 21(4): 267-275 Back to browse issues page
The Effects of Resveratrol Supplementation on the Level of Adiponectin and Leptin in Type 2 Diabetic Patients
Iraj Nabipour 1, Ameneh Gorgin2, Nilofar Motamedi3, Najmeh Hajian2, Mostafa Chashmpoosh2, Faramarz Kooshesh4, Ali Movahed5
1- The Persian Gulf Marine Biotechnology Research Center, The Persian Gulf Biomedical Sciences Research Institute, Bushehr University of Medical Sciences, Bushehr, Iran
2- School of Medicine, Bushehr Universityof Medical Sciences, Bushehr, Iran
3- The Persian Gulf Tropical Medicine Research Center, The Persian Gulf Biomedical Sciences Research Institute, Bushehr University of Medical Sciences, Bushehr, Iran
4- Department of Anesthesiology, School of Paramedicine, Bushehr University of Medical Sciences Bushehr, Iran
5- School of Medicine, Bushehr Universityof Medical Sciences, Bushehr, Iran
The Persian Gulf Tropical Medicine Research Center, The Persian Gulf Biomedical Sciences Research Institute, Bushehr University of Medical Sciences, Bushehr, Iran
Abstract:   (902 Views)
Background: Resveratrol (RSV), one of the most effective natural polyphenolic compounds synthesized by plants, has antioxidant, anti-inflammation and anti-insulin-resistance properties. Some studies suggest that the mechanism of action of RSV is mainly mediated by the deacetylase Sirt1. However, other studies have shown that RSV plays its role through other metabolic routes such as its stimulatory effect on the secretion of adiponectin. Adiponectin is a hormone that plays an important role in the regulation of insu-lin sensitivity and energy homeostasis. In addition, RSV can control obesity by preventing the develop-ment of central leptin resistance. This study aimed to evaluate the effect of RSV on blood concentration of adiponectin and leptin in patients with type 2 diabetes. Materials and methods: This double-blind randomized clinical trial recruited 51 patients with type II diabetes from a previous study. Patients’ demographics and medical history were recorded in an inter-view. The intervention group received 500 mg RSV capsules twice a day for 45 days while the control group received identical placebo capsules. Blood pressure, weight, BMI, lipid profile, blood levels of adi-ponectin, leptin and liver function tests were measured at baseline. Data were analyzed using descriptive statistics and independent t-test in SPSS 18. Results: There were no differences in the concentration of adiponectin and leptin between the two groups. However, Mann-Whitney test revealed a difference in the concentration of leptin between intervention and control groups (p= 0.025). That is, the blood level of leptin was significantly more in the intervention group. Conclusion: The results of this study suggest that supplementation of 1 g per day of RSV for 45 days has no effect on the blood level of adiponectin and leptin in patients with type 2 diabetes.
Keywords: Resveratrol, leptin, adiponectin, type II diabetes
Full-Text [PDF 654 kb]   (364 Downloads)    
Type of Study: Original | Subject: Disorders of Systemic, Metabolic or Environmental Origin
Received: 2018/09/4 | Accepted: 2018/09/4 | Published: 2018/09/4
1. Herman WH, Zimmet P. Type 2 diabetes: an epidemic requiring global attention and urgent action. Diabetes Care 2012; 35(5): 943-4.
2. Lam DW, LeRoith D. The worldwide diabetes epidemic. Curr Opin Endocrinol Diabetes Obes 2012; 19(2): 93-6.
3. Liu M, Zhou L, Xu A, et al. A disulfide-bond A oxidoreductase-like protein (DsbA-L) regulates adiponectin multimerization. Proc Natl Acad Sci U S A 2008; 105(47): 18302-7.
4. Böttner M, Christoffel J, Rimoldi G, et al. Effects of long-term treatment with resveratrol and subcutaneous and oral estradiol administration on the pituitary-thyroid-axis. Exp Clin Endocrinol Diabetes 2006; 114(02): 82-90.
5. Giuliani C, Bucci I, Di Santo S, et al. Resveratrol inhibits sodium/iodide symporter gene expression and function in rat thyroid cells. PloS One 2014; 9(9): e107936.
6. Guerre-Millo M. Adiponectin: an update. Diabetes Metab 2008; 34(1): 8-12.
7. Izadi M, Zarifian A, Eghdami A, et al. Relationship between cardiovascular risk factors and blood adiponectin in diabetic males. Iranian South Med J 2012;15(2):101-8.
8. Lindsay RS, Funahashi T, Hanson RL, et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002; 360(9326): 57-8.
9. Eseberri I, Lasa A, Churruca I, et al. Resveratrol metabolites modify adipokine expression and secretion in 3T3-L1 pre-adipocytes and mature adipocytes. PLoS One 2013; 8(5): e63918.
10. Habauzit V, Morand C. Evidence for a protective effect of polyphenols-containing foods on cardiovascular health: an update for clinicians. Ther Adv Chronic Dis 2012; 3(2): 87-106.
11. Juhasz B, Varga B, Gesztelyi R, et al. Resveratrol: a multifunctional cytoprotective molecule. Curr Pharm Biotechnol 2010; 11(8): 810-8.
12. Giovinazzo G, Ingrosso I, Paradiso A, et al. Resveratrol biosynthesis: plant metabolic engineering for nutritional improvement of food. Plant Foods Hum Nutr 2012; 67(3): 191-9.
13. Wu JM, Wang Z-R, Hsieh T-C, et al. Mechanism of cardioprotection by resveratrol, a phenolic antioxidant present in red wine. Int J Mol Med 2001; 8(1): 3-17.
14. Brasnyó P, Molnár GA, Mohás M, et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr 2011; 106(3): 383-9.
15. Bashmakov YK, Assaad-Khalil S, Petyaev IM. Resveratrol may be beneficial in treatment of diabetic foot syndrome. Med Hypotheses 2011; 77(3): 364-7.
16. Movahed A, Nabipour I, Lieben Louis X, et al. Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients. Evid Based Complement Alternat Med 2013: 1-11.
17. Bhatt JK, Thomas S, Nanjan MJ. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr Res 2012; 32(7): 537-41.
18. Vang O, Ahmad N, Baile CA, et al. What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PloS One 2011; 6(6): e19881.
19. Franco J, Lisboa P, da Silva Lima N, et al. Resveratrol prevents hyperleptinemia and central leptin resistance in adult rats programmed by early weaning. Horm Metab Res 2014; 46(10): 728-35.
20. Palsamy P, Subramanian S. Resveratrol protects diabetic kidney by attenuating hyperglycemiamediated oxidative stress and renal inflammatory cytokines via Nrf2–Keap1 signaling. Biochim Biophys Acta 2011; 1812(7): 719-31.
21. Tomé-Carneiro J, Gonzálvez M, Larrosa M, et al .Grape resveratrol increases serum adiponectin and downregulates inflammatory genes in peripheral blood mononuclear cells: a tripleblind, placebo-controlled, one-year clinical trial in patients with stable coronary artery disease. Cardiovasc Drugs Ther 2013; 27(1): 37-48.
22. Costa Cdos S, Rohden F, Hammes TO, et al. Resveratrol upregulated SIRT1, FOXO1, and adiponectin and downregulated PPARγ1–3 mRNA expression in human visceral adipocytes. Obes Surg 2011; 21(3): 356-61.
23. Szkudelska K, Nogowski L, Szkudelski T. The inhibitory effect of resveratrol on leptin secretion from rat adipocytes. Eur J Clin Invest 2009; 39(10): 899-905.

XML   Persian Abstract   Print

Volume 21, Issue 4 (Iranian South Medical Journal 2018) Back to browse issues page